Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Oral Vinorelbine for HER2+ Metastatic Breast Cancer
NCT00912275Phase 2Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Nov 2008
- Primary completion
- Mar 2015
- Countries
- 1
01
Overview
Phase 2, open-label trial of lapatinib in breast cancer, sponsored by National Taiwan University Hospital. Primary endpoint: Recommended Phase 2 Dose at 4 months. Started Nov 2008; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00912275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00912275.